Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,519 total articles
Guggenheim has reaffirmed a Buy rating on Oracle with a $400 price objective and designated the company its Best Idea heading into 2026. The call accompanies Oracle's plan to raise $45-50 billion in gross proceeds to accelerate Oracle Cloud Infrastructure growth for major customers, even as investors weigh capital intensity and the stock trades far…
Guggenheim has reaffirmed a Buy rating and a $38.00 price objective for Pinterest Inc (PINS) after examining the company's January 2026 audience reach and app download figures. The price target implies roughly 72% upside from the current share price, even as core audience reach and domestic downloads showed weakness. Pinterest is initiating a globa…
Evercore ISI raised its price target for Colgate-Palmolive (CL) to $100 from $94 while keeping an Outperform rating, reflecting momentum in oral care and Hill’s pet nutrition, favorable currency effects in key international markets, and a robust gross margin that supports reinvestment. The stock trades with a premium valuation and recently beat fou…
Leerink Partners began coverage of Waystar Holding (WAY) with an Outperform rating and a $43 price target, implying roughly 62% upside from the stock's current level. The firm points to Waystar's revenue growth, enhanced AI-driven capabilities after the Iodine deal, diversified customer footprint and a strong liquidity position as foundations for m…
Raymond James has initiated coverage of Venture Global (VG) with an Outperform rating and an $11.00 price target, implying about 12% upside from the stock's most recent price of $9.80. The firm points to the company's strong revenue growth and a scalable, faster-than-average LNG delivery model, while third-party data and other analysts flag valuati…
Guggenheim initiated coverage of Avalo Therapeutics Inc. with a Buy rating and a $50.00 price target, pointing to the potential of the company’s AVTX-009 anti-IL-1β program in treating hidradenitis suppurativa. The firm emphasizes AVTX-009’s high affinity and target specificity, a Phase II program with topline data due in the second quarter of 2026…
BTIG has reiterated a Buy rating and a $60 price target on Unity Software (U), citing improving growth trends, early upside from marketing tools and potential from a new D28 product. The stock recently slid to $29.10, down 32.33% over the past week, and is trading slightly below its Fair Value estimate. Other broker moves on Unity range from bullis…
BofA Securities raised its price objective for RTX Corp. to $230 from $215 while maintaining a Buy rating, reflecting the firm's view that the company is making progress on its Geared Turbofan engine issues and benefits from robust demand and a resurgent defense segment. The new target implies roughly 15% upside from RTX's current share price near …
Jefferies has reiterated a Buy rating on Amazon.com Inc. and held its $300 price target, arguing that the stock's current valuation understates early signs of Amazon Web Services (AWS) re-acceleration. The firm points to AWS backlog, October bookings and easier year-over-year comparisons as evidence of potential mid-20s percentage growth in Q4. Mul…
BMO Capital Markets has reaffirmed an Underperform rating and a $94.00 price target on Prudential Financial (PRU), flagging heightened macro volatility and regulatory attention in the company’s Japan operations. The target sits below the stock’s most recent quote of $111.11, and several near-term earnings revisions have already been recorded ahead …
Oracle has outlined a $45-50 billion funding program for calendar year 2026 to accelerate capacity for its Oracle Cloud Infrastructure. Jefferies reiterated a Buy rating with a $400 price target. The financing - split evenly between equity and debt - is intended to bridge projected 2026 capital needs and current liquidity while supporting contracte…
BofA Securities raised its price objective on Baker Hughes to $65 from $55 and affirmed a Buy rating after attending the company's 2026 Annual Meeting in Florence. The broker pointed to a shift in Industrial & Energy Technology orders away from LNG toward gas compression, clean energy, industrial technology and power systems, and highlighted an exp…
BMO Capital has reaffirmed an Outperform rating on Allstate and lifted its price target to $249.00, citing a recovered capital position after adjustments for Life & Health disposals and parent cash, a declining reinsurance expense outlook, and expectations that the insurer will refresh its share repurchase authorization in the first half of 2026. O…
Wells Fargo raised its price objective for Colgate-Palmolive to $94 from $86, applying a higher valuation multiple to the firm's 2027 earnings projection, but left its rating unchanged at Equal Weight. The move arrives after Colgate reported Q4 2025 results that beat expectations and as another firm, TD Cowen, lifted its target to $96 and maintaine…
BTIG has reiterated a Buy rating and $60 price target on Bill.com (BILL) ahead of the company’s second-quarter fiscal 2026 earnings report on February 5. The research firm highlights valuation support tied to Capital One’s acquisition of Brex, an 83.85% gross profit margin, and a path to strengthen Rule of 40 performance. While revenue is expected …
Wells Fargo reduced its 12-month price target on Aon to $443 from $448 but retained an Overweight rating. The move follows Aon’s detailed 2026 guidance that projects robust adjusted EPS growth, mid-single-digit or greater organic growth, margin expansion, double-digit free cash flow growth and $1 billion in share repurchases. Aon’s Q4 2025 adjusted…
Wells Fargo increased its price objective for Hartford Financial Services Group to $156 from $153 and maintained an Overweight rating, citing moderating auto pricing and expected improvements in customer retention. The firm highlighted Hartford’s growth initiatives and favorable valuation metrics, while the company’s strong fourth-quarter 2025 resu…
Wells Fargo increased its price target for Regeneron Pharmaceuticals to $800 from $745 while retaining an Equal Weight rating. The firm based the revision on a more optimistic timeline for Dupixent patent protection and modeled stronger earnings and profit share for the drug, even as it remains cautious about Regeneron’s LAG3 program and awaits mul…
Stifel raised its price target on Liberty Energy to $28 from $23 and kept a Buy rating after the company reported stronger-than-expected fourth-quarter EBITDA and outlined accelerated power generation goals. Piper Sandler separately upgraded the stock and hiked its target, citing growth in Liberty’s power business and recent data center agreements.
Wells Fargo increased its price target on ArcBest Corp to $85 from $74 while keeping an Equal Weight rating, citing better Asset-Based volume and margin trends. The firm raised near-term and full-year earnings estimates but notes its target remains below ArcBest's current share price and InvestingPro's Fair Value, suggesting limited upside. ArcBest…
TD Cowen raised its price target on Church & Dwight Co. Inc. to $99 from $97 while keeping a Hold rating after the company reported slightly better-than-expected fourth-quarter earnings. Management issued 2026 guidance projecting faster organic growth and higher earnings per share, prompting TD Cowen and JPMorgan to revise forecasts and targets. Re…
Stifel has increased its price target for Baker Hughes to $63.00 from $58.00 while retaining a Buy rating, citing strengthened confidence in the company’s Industrial & Energy Technology (IET) segment after attending Baker Hughes’ 2026 Annual Meeting in Florence, Italy. The stock trades near its 52-week high and has returned roughly 30.09% over six …
TD Cowen has raised its price target on Colgate-Palmolive to $96 from $86 while maintaining a Buy recommendation. The firm cited a slight fourth-quarter earnings beat, 2026 guidance consistent with mid-single-digit EPS growth at the high end of the range, and resilient international execution as reasons for the upgrade. The new target implies modes…
Jefferies raised its price target on ArcBest Corp to $110 from $95 while keeping a Buy rating, following fourth-quarter results that showed better-than-expected Asset-Based operating ratio performance. The company beat revenue estimates but missed on adjusted EPS, and Jefferies highlighted potential margin improvement into early 2026 and strong ear…
TD Cowen raised its price target on Palvella Therapeutics (NASDAQ:PVLA) to $190.00 from $133.00 and kept a Buy rating after a successful FDA Breakthrough Therapy Designation advice meeting for QTORIN rapa in congenital vascular malformations. Senior FDA division leadership and key opinion leaders expressed supportive views at the meeting, and Palve…
